Company Overview of Eagle Pharmaceuticals Inc.
Eagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers argatroban to treat heparin-induced thrombocytopenia; and Ryanodex injectable suspension for the treatment of malignant hyperthermia. It develops EP-3101, a bendamustine ready to dilute (RTD) liquid and EP-3102, a bendamustine short infusion time RTD liquid for the treatment of chronic lymphocytic leukemia and indolent non-Hodgkin's lymphoma;; and EP-4104, a dantrolene for the treatment of exertional heat stroke. The company also develops EP-5101 (pemetrexed) as RTD liquid, whi...
50 Tice Boulevard
Woodcliff Lake, NJ 07677
Founded in 2007
Key Executives for Eagle Pharmaceuticals Inc.
Chief Executive Officer, President, Director and Member of Executive Committee
Total Annual Compensation: $449.6K
Chief Financial Officer
Total Annual Compensation: $265.9K
Chief Scientific Officer and Executive Vice President
Total Annual Compensation: $352.4K
Compensation as of Fiscal Year 2014.
Eagle Pharmaceuticals Inc. Key Developments
Eagle Pharmaceuticals, Inc. Appoints Michael Moran as U.S. Head of Sales
Feb 4 16
Eagle Pharmaceuticals Inc. announced that it has appointed Michael Moran to the role of U.S. Head of Sales, effective immediately. Michael Moran is an industry veteran with more than 15 years of experience in pharmaceutical sales. Prior to joining Eagle he spent seven years in various leadership roles at GlaxoSmithKline, including most recently the role of field vice president.
Eagle Pharmaceuticals Announces Commercial Availability of Docetaxel Injection
Feb 2 16
Eagle Pharmaceuticals announced the shipment and commercial availability of Alcohol-Free Docetaxel Injection (“Docetaxel Injection”). Docetaxel Injection is approved for the treatment of breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma, and head and neck cancer. Docetaxel Injection is the first alcohol-free formulation approved in the U.S. Additional features of this product are: presents as one, pre-filled vial that does not require mixing; is available in three different dosages: 20mg/1ml, 80mg/4mL, and 160mg/8mL; and 24 hours of stability at final dilution strength.
FDA Grants Fast Track Designation to Eagle Pharmaceuticals Inc.'s RYANODEX for Treatment of Exertional Heat Stroke
Feb 1 16
Eagle Pharmaceuticals announced that the U.S. Food and Drug Administration has granted Fast Track designation to its RYANODEX (dantrolene sodium for injectable suspension) for the treatment of exertional heat stroke, an investigational new indication for the product. The FDA's Fast Track program facilitates the development and review of drugs intended to treat serious conditions and address an unmet medical need. A drug development program with Fast Track designation is afforded greater access to the FDA for the purpose of expediting the drug's development, review and potential approval to get important new drugs to the patient earlier.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries